These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 6183494)

  • 1. [Method of evaluating the activity of enzymes metabolizing drugs].
    Semeniuk AV; Kolesnikova LI; Kulikov VIu; Nedle'kina SV; Salganik RI
    Lab Delo; 1982; (10):31-3. PubMed ID: 6183494
    [No Abstract]   [Full Text] [Related]  

  • 2. [Indirect method of determining drug-metabolizing enzyme activity and its clinical application].
    Nedel'kina SV; Dianova II; Subbotina RS; Salganik RI
    Vopr Med Khim; 1977; (6):844-7. PubMed ID: 595490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of antipyrine kinetics by measurement in saliva.
    Fraser HS; Mucklow JC; Murray S; Davies DS
    Br J Clin Pharmacol; 1976 Apr; 3(2):321-5. PubMed ID: 973966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis.
    Harman AE; Priestly BG; Frewin DB
    Clin Exp Pharmacol Physiol; 1977; 4(6):593-6. PubMed ID: 589875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine kinetics in liver disease and liver transplantation.
    Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE
    Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary antipyrine half-life: a useful measure of hepatic drug metabolism.
    Brooks PM; Bell MA; Burns H
    Br J Clin Pharmacol; 1976 Oct; 3(5):945-6. PubMed ID: 973995
    [No Abstract]   [Full Text] [Related]  

  • 7. Ethanol and antipyrine clearance.
    Døssing M; Andreasen PB
    Clin Pharmacol Ther; 1981 Jul; 30(1):101-4. PubMed ID: 7237890
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of a non-steroid anti-inflammatory agent on the drug metabolizing activity of the human liver.
    Gachályi B; Vas A; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1984 Jul; 22(7):353-4. PubMed ID: 6469424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antipyrine metabolism in cigarette smokers in Indian population.
    Uppal R; Garg SK; Sharma PR; Nair CR; Chaudhury RR
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):269-71. PubMed ID: 7450928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipyrine repeatability and comparison of the powder and capsule formulations.
    Edeki T; Turner P
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):70-5. PubMed ID: 7757313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
    Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
    Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing antipyrine elimination.
    Stevenson IH
    Br J Clin Pharmacol; 1977 Jun; 4(3):261-5. PubMed ID: 332216
    [No Abstract]   [Full Text] [Related]  

  • 13. [Age-related microsomal hydroxylase activity in virtually healthy persons].
    Subbotina RS
    Vopr Med Khim; 1982; 28(4):94-5. PubMed ID: 7113062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.
    Eichelbaum M; Ochs HR; Roberts G; Somogyi A
    Arzneimittelforschung; 1982; 32(5):575-8. PubMed ID: 7201837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of nonmetabolized antipyrine in human urine].
    Gozhenko AI; Dolomatov SI; Mosklaenko TIa; Iakimenko LV; Ambrosiĭchuk EV; Dolomatova EA
    Eksp Klin Farmakol; 2004; 67(3):59-60. PubMed ID: 15341072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J; Alsar Ortiz MJ
    Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic disposal of antipyrine and lipid peroxidation indices in volunteers jointly exposed to industrial organic solvents and ethanol.
    Wiśniewska-Knypl J; Jajte J; Wrońska-Nofer T; Kostrzewski P
    Pol J Occup Med Environ Health; 1993; 6(2):157-67. PubMed ID: 8219907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipyrine half-life in hyperthyroidism.
    Obel AO; Ng'ang'a J; Gitau W
    East Afr Med J; 1981 Apr; 58(4):258-62. PubMed ID: 7261979
    [No Abstract]   [Full Text] [Related]  

  • 19. Antipyrine kinetics in Nigerian women in chronic renal failure.
    Iyun AO; Tucker GT
    Afr J Med Med Sci; 1982 Mar; 11(1):7-9. PubMed ID: 6291357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of sulfamerazine and antipyrine in neonatal and young lambs.
    De Backer P; Belpaire FM; Bogaert MG; Debackere M
    Am J Vet Res; 1982 Oct; 43(10):1744-51. PubMed ID: 7149373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.